Last week, a new paper, which evaluates the use of the Liposcale® test as a predictor of premature cardiovascular disease (PRESARV-SEA Study), was published. Beyond levels of LDL-C, results reported in the article support the relevance of LDL cholesterol composition and size on premature cardiovascular disease progression and its potential as a new biomarker for residual cardiovascular risk.
Liposcale® test allows determining both the basic lipid profile including total cholesterol, LDL, HDL, non-HDL and triglycerides, and a more advanced lipoprotein profile that includes the lipid composition, particle size and concentration of the main lipoprotein classes (VLDL, LDL, and HDL), as well as the particle concentration of 9 subclasses. The complete characterization of the lipoprotein profile facilitates the detection of individuals with an increased cardiovascular disease (CVD) risk.
The Liposcale® test, in addition to being a very useful tool both in research studies and in clinical trials, is already used in clinical practice in different hospitals and clinical analysis laboratories. You can see an example of the clinical Liposcale® report here. Please contact us if you want more information about our services.
